Previous 10 |
home / stock / ophly / ophly news
Summary It’s among the prohibitively expensive biologic pharmaceuticals being replaced by cheaper “biosimilar” copycats. Relief is on the way for patients who need Humira, a product made by AbbVie. Several drugmakers are expected to begin offering biosimilar ver...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: ra2 studio/Shutterstock Shares of Fate Therapeutics (NASDAQ: FATE ) stock are up 3% following a massive purchase by two of Cathie Wood’s exchange-traded funds (ETFs). Fate is a clinical stage biotec...
Ono Pharmaceutical press release ( OTCPK:OPHLF ): Q1 GAAP EPS of ¥60.36. Revenue of ¥106.72B (+22.2% Y/Y). For further details see: Ono Pharmaceutical GAAP EPS of ¥60.36, revenue of ¥106.72B
The subsector with the best value and quality scores is pharmaceutical/biotechnology. Life science tools and healthcare equipment are the most overvalued. Fast facts on IDNA. A list of cheap stocks. For further details see: IDNA: Healthcare Dashboard For February
The following slide deck was published by Ono Pharmaceutical Co., Ltd. in conjunction with their 2022 Q1 earnings call. For further details see: Ono Pharmaceutical Co., Ltd. 2022 Q1 - Results - Earnings Call Presentation
Ono Pharmaceutical (OTC:OPHLF): Q1 GAAP EPS of ¥48.22. Revenue of ¥87.36B (+16.6% Y/Y). Press Release For further details see: Ono Pharmaceutical reports Q1 results
News, Short Squeeze, Breakout and More Instantly...
Ono Pharmaceutical Co Ltd ADR Company Name:
OPHLY Stock Symbol:
OTCMKTS Market:
ONO Enters into a Definitive Agreement to Acquire Deciphera Pharmaceuticals PR Newswire OSAKA, Japan , April 30, 2024 /PRNewswire/ -- ONO Pharmaceutical, Co., Ltd., (TSE: 4528, Representative Director, Chairman of the Board and Chief Executive Officer: Gyo Saga...
Ono Expands Investment in Ono Venture Investment Fund I, L.P. to US$200 Million PR Newswire - Double the investment scale to accelerate open innovation and make strategic investments in bio-venture companies - OSAKA, Japan , Dec. 1, 2023 /PRNewswire/ -- O...